Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex Reports Third Quarter 2022 Financial Results
October 27, 2022 4:01 PM EDTProduct revenue of $2.33 billion, an 18% increase compared to Q3 2021
Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion
Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities:
Initiating global exa-cel regulatory submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Initiated Phase 3 clinical studies of VX-548, a novel, selective NaV1.8 inhibitor, in acute pain
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third... More
